CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
Name:
PIIS2352302618300395.pdf
Size:
341.3Kb
Format:
PDF
Description:
Full text, Open Access article
Authors
Gleeson, MPeckitt, C
To, Y
Edwards, L
Oates, J
Wotherspoon, A
Attygalle, A
Zerizer, I
Sharma, B
Chua, S
Begum, R
Chau, I
Johnson, P
Ardeshna, K
Hawkes, E
Macheta, M
Collins, G
Radford, John A
Forbes, A
Hart, A
Montoto, S
McKay, P
Benstead, K
Morley, N
Kalakonda, N
Hasan, Y
Turner, D
Cunningham, D
Affiliation
The Royal Marsden NHS Foundation Trust, London and Surrey, UKIssue Date
2018-05
Metadata
Show full item recordAbstract
Outcomes with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or CHOP-like chemotherapy in peripheral T-cell lymphoma are poor. We investigated whether the regimen of gemcitabine, cisplatin, and methylprednisolone (GEM-P) was superior to CHOP as front-line therapy in previously untreated patients.Citation
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. 2018, 5(5): e190-e200 Lancet HaematolJournal
The Lancet HaematologyDOI
10.1016/S2352-3026(18)30039-5PubMed ID
29703335Type
ArticleLanguage
enDescription
Lymphoma Research TeamISSN
2352-3026ae974a485f413a2113503eed53cd6c53
10.1016/S2352-3026(18)30039-5
Scopus Count
Collections
Related articles
- Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
- Authors: Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWM
- Issue date: 2019 May
- Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
- Authors: Dupuis J, Morschhauser F, Ghesquières H, Tilly H, Casasnovas O, Thieblemont C, Ribrag V, Bossard C, Le Bras F, Bachy E, Hivert B, Nicolas-Virelizier E, Jardin F, Bastie JN, Amorim S, Lazarovici J, Martin A, Coiffier B
- Issue date: 2015 Apr
- Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
- Authors: Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y
- Issue date: 2014 Aug
- Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
- Authors: Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U
- Issue date: 2017 Aug
- CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.
- Authors: Cai MC, Cheng S, Wang X, Hu JD, Song YP, Huang YH, Yan ZX, Jiang YJ, Fang XS, Zheng XY, Dong LH, Ji MM, Wang L, Xu PP, Zhao WL
- Issue date: 2020 Apr 30